Our Vision

To provide high-quality affordable healthcare solutions to combat AMR.

Welcome to Rapiddx

We are developing a rapid Antimicrobial susceptibility test (AST) platform to reduce the time gap between sample collection and susceptibility detection. Our vision is to provide high-quality affordable healthcare solutions to combat AMR.

Anti Microbial Resistance – Global threat

In India, 2 million deaths estimated due to AMR by the year 2050
In USA, 2.8 million AMR incidences each year
By the year 2050, the global cost of AMR will be up to $100 trillion

Our Technology

We employ Mechatronics, Microfluidics, and data analytics to provide cutting-edge solutions to AMR’s quest.

Mechatronics

We use mechanical, electronics, & embedded programming skills to prioritize system-based thinking & interdisciplinary problem-solving.

Microfluidics

Our self-reliant Microfluidics chip offers a number of advantages over conventional macroscale analytics like smaller reagent volume requirement, greater flexibility & affordability. Ease of use & low production cost makes it attractive to hospital and pathology work.

Data Analytics

Increase your work efficiency and improve performance by discovering patterns in data.

News and Media

Rapiddx Technologies selected for the AIT 2021 supported by Swissnex in India and Consulate general of Switzerland. The digital version of AIT India aims to transform high-level applied research into market applications.

rPASA™

Know antimicrobial susceptibility on Time

Our platform uses patented sensor technology to test susceptibility directly from a clinical sample on a microfluidics platform. Patients, pathology staff, and hospitals are three main stakeholders who get directly benefited.

5 Hrs

Susceptibility within